PharVision Advisers LLC Buys Shares of 1,384 Danaher Corporation $DHR

Key Points

• PharVision Advisers LLC has made a new investment of approximately $284,000 in Danaher Corporation, acquiring 1,384 shares as reported in their latest SEC filing.
• Institutional investors own approximately 79.05% of Danaher’s stock, indicating a strong interest from hedge funds, including substantial increases in holdings by firms like Bank Pictet & Cie Europe AG and Ethic Inc.
• Danaher reported $1.80 EPS for the latest quarter, surpassing expectations, with a projected FY 2025 EPS guidance of 7.700-7.800.

PharVision Advisers LLC acquired a new position in shares of Danaher Corporation (NYSE:DHR - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,384 shares of the conglomerate's stock, valued at approximately $284,000.

A number of other institutional investors have also added to or reduced their stakes in DHR. GHP Investment Advisors Inc. increased its position in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock valued at $25,000 after acquiring an additional 99 shares during the period. Heck Capital Advisors LLC acquired a new position in Danaher in the 4th quarter valued at approximately $27,000. Sierra Ocean LLC increased its position in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after acquiring an additional 76 shares during the period. Smallwood Wealth Investment Management LLC acquired a new position in Danaher in the 1st quarter valued at approximately $31,000. Finally, Dunhill Financial LLC increased its position in Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock valued at $34,000 after acquiring an additional 67 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Teri List sold 2,778 shares of Danaher stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 11.20% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have issued reports on DHR. Wells Fargo & Company decreased their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. Evercore ISI dropped their price target on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a research report on Tuesday, July 8th. Barclays reiterated an "overweight" rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a research report on Tuesday, June 24th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Danaher from $240.00 to $235.00 in a research report on Thursday, June 5th. Finally, Royal Bank Of Canada set a $241.00 price objective on shares of Danaher in a research report on Tuesday, September 2nd. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $246.35.

Danaher Stock Down 2.2%

Shares of NYSE:DHR traded down $4.39 during trading on Tuesday, reaching $194.24. 3,344,891 shares of the stock were exchanged, compared to its average volume of 2,899,976. The firm has a market cap of $139.09 billion, a price-to-earnings ratio of 41.33, a price-to-earnings-growth ratio of 2.77 and a beta of 0.75. The stock has a fifty day moving average of $201.95 and a two-hundred day moving average of $199.23. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $279.90.

Danaher (NYSE:DHR - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business's revenue was up 3.4% on a year-over-year basis. During the same period last year, the company earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio is currently 27.23%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.